Neda Rasouli, MD
Enriched profileProfessor, Medicine-Endocrinology/Metabolism/Diabetes · University of Colorado Anschutz School of Medicine
Neda Rasouli is Professor, Medicine-Endocrinology/Metabolism/Diabetes at University of Colorado Anschutz School of Medicine. OpenAlex indexes 215 publications with 10,981 citations (h-index 44); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Neda Rasouli, MD, is Professor, Medicine-Endocrinology/Metabolism/Diabetes at University of Colorado Anschutz School of Medicine. The public record shows 215 publications with 10,981 citations (h-index 44), centered on Type 2 Diabetes. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2026 · European heart journal
- Top research focus: Type 2 Diabetes
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Rare and Atypical Diabetes Network
Sponsor: University of South Florida
- Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications
Sponsor: University of Colorado, Denver
- Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
Sponsor: University of Colorado, Denver
Industry payments
Updated 27 Aug 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novo Nordisk ASProgram year20259 payments$21,705openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202512 payments$15,015openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20258 payments$13,152openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
89.3%GLP-1 receptor agonist45.6%Ozempic72%Mounjaro28%Part D<11 patientsInsulin Analog16.5%Lantus Solostar100%Part D<11 patientsCardiovascular
10.7%Angiotensin receptor blocker (ARB)10.7%Losartan Potassium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.
European heart journal
Article2026 - Role of 2-hour plasma glucose in assessing pre-diabetes risk: insights from the vitamin D and type 2 diabetes (D2d) study cohort.
BMJ open diabetes research & care
Letter2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/neda-rasouli-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/neda-rasouli-66326b39
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/nedarasouli2
Mentions by others
where others cite or feature them- X / Twitter
x.com/GlobalHealth_TV/status/1569328129172291584
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtu.be/O4bGs9uBqnA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtu.be ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cumedicine.us ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership roles
journal and society appointments- Past President
American Federation for Medical Research (AFMR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗ - Member
American Diabetes Association
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- Director
CU Diabetes and Endocrinology Clinical Trial Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.cuanschutz.edu ↗
Media & interviews
press, podcasts and appearances- Featured expert
"What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight-Loss Drug" (CU Anschutz News, May 2026) - discussed ATTAIN-1 trial results and obesity as a disease
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medscape.com ↗
- Guest
"Diabetes Care On Air" podcast (American Diabetes Association) - discussed STRIDE trial findings on semaglutide in symptomatic peripheral artery disease and type 2 diabetes, Episode 35, Sept 2025
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →music.amazon.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council